CytoDyn Files an IND and a Phase 2 Protocol with the FDA for the Treatment of NASH with Leronlimab

    NEXT STORY
    Curetis and OpGen Enter Into Definitive Agreement to Combine Businesses
    PREV STORY
    Opthea’s Phase 2b Study of OPT-302 in Wet AMD to be Presented in Late-Breaking Session of EURETINA
    Subscribe to PM360
    Print Subscription
    Follow Us

    Experts on Call

    Get in touch with PM360 Experts On Call

    Ads

    You May Also Like

    Helsinn signs exclusive distribution and license agreements with Blanver and Varifarma for Pracinostat in South America

    author_avatar
    NASDAQ Market News

    Radius Health Announces First Quarter 2020 Operating Results

    author_avatar
    NASDAQ Market News

    ADMA Biologics Strengthens Patent Portfolio Through Newly Issued U.S. Patent for Immunotherapeutic Methods

    RAMSEY, N.J. and BOCA RATON, Fla., July 31, 2017 (GLOBE NEWSWIRE) -- ADMA Biologics, ...

    author_avatar
    NASDAQ Market News